HRSA’s 340B Rebate Model remains temporarily blocked following a series of federal court rulings, most recently a decision by a federal appeals court in Boston denying the federal government’s request to restart the pilot. As a result, the model remains on hold beyond its planned January 1, 2026 effective date, with implementation paused while litigation continues and HHS signals it may no longer pursue appellate relief—shifting the outlook toward administrative reconsideration rather than near-term implementation.
Below is a summary of what happened, where things stand now, and what would need to occur for the rebate model—or a revised approach—to move forward.
What Happened
On December 29, a federal judge in the U.S. District Court for the District of Maine issued a nationwide injunction preventing the Health Resources and Services Administration (HRSA) from launching the 340B Rebate Model. The court found that HRSA’s administrative record likely failed to adequately consider the impact of a rebate-based model on 340B hospitals.
HRSA operates under the Department of Health and Human Services (HHS). After the ruling, HHS asked both the district court and the federal appeals court to pause the injunction and allow the rebate model to proceed while the case was under appeal. Those requests were denied.
Most recently, on January 7, a three-judge panel of the U.S. Court of Appeals for the First Circuit unanimously denied HHS’ emergency request to lift the injunction, finding that the agency had not shown it was likely to succeed on the merits of its appeal and concluding that the injunction appropriately preserves the long-standing status quo of the 340B program.
During this period, HRSA lacks authority to implement the rebate model and must continue administering the 340B program under existing pricing and purchasing frameworks.
HRSA formally paused implementation of the rebate pilot on December 31, one day before it was scheduled to take effect. Following the appeals court decision, HHS indicated it plans to withdraw its appeal.
How Long Will the Block Last?
The block remains temporary, but its duration is increasingly uncertain. With HHS signaling plans to withdraw its appeal, the pause is no longer tied to a defined appellate timeline and may extend indefinitely while HRSA reassesses its approach.
There is currently no defined end date for the pause, and the rebate model will remain on hold unless and until HRSA takes further action through a revised or new administrative process.
What Would Need to Happen for the Rebate Model — or a Revised Approach — to Move Forward?
With litigation no longer the primary path forward, any future movement would require action by HRSA outside the current court process. Potential scenarios include:
- HRSA revises and reintroduces the model
HRSA could modify the rebate model to address the concerns raised by the courts—particularly around administrative process and impact analysis—and reintroduce it through a revised approach. This would likely involve additional delay and could result in meaningful changes to how the model operates.
- HRSA restarts the proposal through a different process
Rather than reviving the current pilot, HRSA could pursue a different regulatory or policy pathway to rebate-based pricing within the 340B program, such as new guidance or rulemaking. This would further extend timelines.
- HRSA formally withdraws and reconsiders the model
HRSA could step away from the current proposal entirely and pursue alternative policy options through future pilots, rulemaking, or other administrative mechanisms. This path would delay implementation further and could materially change the structure of any future rebate-based approach.
Until one of these steps occurs, HRSA does not have authority to implement a rebate-based model, and existing 340B pricing and purchasing practices remain in place.
What This Means for 2026 Planning
The injunction and subsequent developments provide short-term operational stability, but continued long-term uncertainty.
Covered entities should:
- Continue operating under current 340B frameworks
- Avoid assuming the rebate model will be implemented in its original form
- Monitor developments closely as HRSA determines next steps, which may include withdrawal, revision, or reintroduction through a new process
Notably, the Inflation Reduction Act’s Medicare drug price negotiation program took effect on January 1 as planned and is not impacted by the 340B rebate pilot pause.
Bottom Line
The 340B Rebate Model remains paused, and with HHS signaling it may withdraw its appeal, there is no immediate path to implementation. Any future movement is more likely to come through reconsideration, revision, or reframing by HRSA rather than through the courts.
As always, ACI continues to closely monitor developments related to the 340B Rebate Model and prepare our clients for whichever path emerges next—whether that means continued delay, a revised proposal, or broader policy shifts. Our focus remains on helping organizations stay informed, compliant, and operationally ready amid ongoing uncertainty.
Additional Resources
For official updates and background information on the 340B program, readers may reference the HRSA Office of Pharmacy Affairs (OPA) website: https://www.hrsa.gov/opa
Note: Information on this page reflects HRSA’s general 340B program materials and should be read in light of current court orders and HRSA’s paused implementation of the rebate model.